ArticleOncogene2004
Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma.
Article in Oncogene, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 70 citations in OpenAlex.
- Tumor immune microenvironment in therapy-naive esophageal adenocarcinoma could predict the nodal status.Cancer medicine · 2023Article
- Analysis of immune related gene expression profiles and immune cell components in patients with Barrett esophagus.Scientific reports · 2022Article
- From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma.Biochimica et biophysica acta. Reviews on cancer · 2019Review
- Barrett's Esophagus: A Comprehensive and Contemporary Review for Pathologists.The American journal of surgical pathology · 2016Review
- An Integrative Pharmacogenomic Approach Identifies Two-drug Combination Therapies for Personalized Cancer Medicine.Scientific reports · 2016Article
- Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1.Digestive diseases and sciences · 2014Article
- Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction.Cancer biology & therapy · 2013Review
- Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity.Nature genetics · 2013Article
- Vemurafenib: the first drug approved for BRAF-mutant cancer.Nature reviews. Drug discovery · 2012Review
- Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells.American journal of physiology. Gastrointestinal and liver physiology · 2012Article
- Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia.PloS one · 2012Article
- Locally advanced cancer of the esophagus, current treatment strategies, and future directions.Frontiers in oncology · 2012Article
- Targeting the human EGFR family in esophagogastric cancer.Nature reviews. Clinical oncology · 2011Review
- Biology of Barrett's esophagus and esophageal adenocarcinoma.Gastrointestinal endoscopy clinics of North America · 2011Review
- Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations.PloS one · 2010Article
- Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues.The Journal of molecular diagnostics : JMD · 2010Article
- Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.International journal of cancer · 2009Article
- Esophageal adenocarcinoma arising in Barrett esophagus.Cancer letters · 2009Review
- K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma.Pathology oncology research : POR · 2008Article
- Selective Raf inhibition in cancer therapy.Expert opinion on therapeutic targets · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Activation of the Raf/MEK/ERK (MAPK) signal transduction cascade by RAS mutations has been found in a variety of human cancers. Mutations of BRAF provide an alternative route for activation of this signalling pathway. To determine the role of mutations in BRAF and KRAS2 in the neoplastic progression of Barrett's adenocarcinoma, we analysed both genes for common mutations. After microdissection, DNA of 19 Barrett's adenocarcinomas, 56 Barrett's intraepithelial neoplasias (n=29 low-grade intraepithelial neoplasia (LGIN) and n=27 high-grade intraepithelial neoplasia (HGIN)), 30 Barrett's mucosa without neoplasia and normal squamous, as well as gastric epithelium, were analysed for BRAF and KRAS2 mutation. Activating BRAF mutations were identified in 2/19 Barrett's adenocarcinomas (11%) and in 1/27 HGIN (4%). KRAS2 mutations were found in four out of 19 (21%) Barrett's adenocarcinomas examined and in three cases of HGIN (11%). In LGIN as well as in normal gastric or oesophageal mucosa, neither BRAF nor KRAS2 mutations were detected. All lesions with KRAS2 mutations had an intact BRAF gene. The status of mismatch-repair proteins was neither related to BRAF nor KRAS2 mutations. These data indicate that RAS or BRAF mutations are detected in about 32% of all Barrett's adenocarcinomas. We conclude that the disruption of the Raf/MEK/ERK (MAPK) kinase pathway is a frequent but also early event in the development of Barrett's adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.